 |
12 Diseases |  |
17 Trials |
|
17 Trials |  |
2487 News |  |
| «12...13141516171819202122232425» |
- || Aimovig (erenumab) / Amgen, Novartis
Adverse events: Have you had any side effects from #Aimovig? (Twitter) - Apr 18, 2019
- ||||| Aimovig (erenumab-aooe) / Amgen, Novartis
New P4 trial: Effect of Erenumab-aooe on Disability and Work Productivity in Employed Subjects With Episodic Migraine (clinicaltrials.gov) - Apr 10, 2019
P4, N=240, Not yet recruiting, Sponsor: Amgen
- || Aimovig (erenumab) / Amgen, Novartis
@Novartis und das amerikanische Partnerunternehmen @Amgen kriegen sich wegen dem Migränemedikament #Aimovig in die Haare. Fällt die Partnerschaft der beiden Firmen dem kommerziellen Erfolg des Präparats zum Opfer? $NOVN $NVS (Twitter) - Apr 5, 2019
- | Aimovig (erenumab-aooe) / Amgen, Novartis
Enrollment open: Imaging the Migraine Brain Pre- and Post-Erenumab (clinicaltrials.gov) - Apr 5, 2019
P4, N=50, Recruiting, Sponsor: Mayo Clinic
Not yet recruiting --> Recruiting
- ||| Aimovig (erenumab) / Amgen, Novartis
Please share @Novartis @brainfoundoz #migraine #aimovig #NoAimovigNoVote #auspol #AusVotes2019 (Twitter) - Apr 4, 2019
- |||| Aimovig (erenumab) / Amgen, Novartis
Novartis sues Amgen over migraine treatment Aimovig https://t.co/w5NW4ZrQi5 (Twitter) - Apr 4, 2019
- | Aimovig (erenumab) / Amgen, Novartis
Review, Journal: Erenumab is effective in reducing migraine frequency and improving physical functioning. (Pubmed Central) - Apr 3, 2019
Not yet recruiting --> Recruiting No abstract available
- |||||||||| Aimovig (erenumab-aooe) / Amgen, Novartis
New P3 trial: DRAGON: Study of Efficacy and Safety of Erenumab in Adult Chronic Migraine Patients (clinicaltrials.gov) - Mar 7, 2019
P3, N=550, Not yet recruiting, Sponsor: Novartis Pharmaceuticals
- |||| Aimovig (erenumab-aooe) / Amgen, Novartis
Enrollment open, Head-to-Head: HER-MES: Head-to-head Study of Erenumab Against Topiramate in Patients With Episodic and Chronic Migraine (clinicaltrials.gov) - Feb 26, 2019
P4, N=700, Recruiting, Sponsor: Novartis Pharmaceuticals
No abstract available Not yet recruiting --> Recruiting
- |||||||||| Aimovig (erenumab-aooe) / Amgen, Novartis
New P3 trial: OASIS (EM): Efficacy and Safety of Erenumab in Pediatric Participants With Episodic Migraine (clinicaltrials.gov) - Feb 10, 2019
P3, N=456, Not yet recruiting, Sponsor: Amgen
- |||||||||| Aimovig (erenumab-aooe) / Amgen, Novartis
New P3 trial: OASIS (CM): Efficacy and Safety of Erenumab in Pediatric Subjects With Chronic Migraine (clinicaltrials.gov) - Feb 6, 2019
P3, N=286, Not yet recruiting, Sponsor: Amgen
- ||||| Aimovig (erenumab-aooe) / Amgen, Novartis
New P4 trial, Head-to-Head: HER-MES: Head-to-head Study of Erenumab Against Topiramate in Patients With Episodic and Chronic Migraine (clinicaltrials.gov) - Feb 4, 2019
P4, N=700, Not yet recruiting, Sponsor: Novartis Pharmaceuticals
- |||||||||| Aimovig (erenumab-aooe) / Amgen, Novartis
New P3 trial: A Controlled Trial of Erenumab in Migraine Prevention (clinicaltrials.gov) - Jan 23, 2019
P3, N=256, Not yet recruiting, Sponsor: Amgen
- | Aimovig (erenumab-aooe) / Amgen, Novartis
New P4 trial: Imaging the Migraine Brain Pre- and Post-Erenumab (clinicaltrials.gov) - Dec 12, 2018
P4, N=50, Not yet recruiting, Sponsor: Mayo Clinic
- | Aimovig (erenumab-aooe) / Amgen, Novartis
Enrollment closed: LIBERTY: A Study Evaluating the Effectiveness of AMG 334 Injection in Preventing Migraines in Adults Having Failed Other Therapies (clinicaltrials.gov) - Sep 10, 2018
P3, N=246, Active, not recruiting, Sponsor: Novartis Pharmaceuticals
Not yet recruiting --> Recruiting Recruiting --> Active, not recruiting
- || Aimovig (erenumab-aooe) / Amgen, Novartis
Trial completion date, Trial primary completion date: AMG 334 20160172 Pediatric Migraine PK Study. (clinicaltrials.gov) - Jul 18, 2018
P1, N=60, Recruiting, Sponsor: Amgen
Recruiting --> Active, not recruiting Trial completion date: Apr 2020 --> Sep 2021 | Trial primary completion date: May 2019 --> Dec 2020
- ||| Aimovig (erenumab-aooe) / Amgen, Novartis
Enrollment open: AMG 334 20160172 Pediatric Migraine PK Study. (clinicaltrials.gov) - Jun 2, 2018
P1, N=60, Recruiting, Sponsor: Amgen
Trial completion date: Apr 2020 --> Sep 2021 | Trial primary completion date: May 2019 --> Dec 2020 Not yet recruiting --> Recruiting
- |||||| Aimovig (erenumab-aooe) / Amgen, Novartis
Enrollment open: LIBERTY: A Study Evaluating the Effectiveness of AMG 334 Injection in Preventing Migraines in Adults Having Failed Other Therapies (clinicaltrials.gov) - May 1, 2018
P3, N=220, Recruiting, Sponsor: Novartis Pharmaceuticals
Not yet recruiting --> Recruiting Active, not recruiting --> Recruiting
- ||| Aimovig (erenumab-aooe) / Amgen, Novartis
New P1 trial: AMG 334 20160172 Pediatric Migraine PK Study. (clinicaltrials.gov) - Apr 17, 2018
P1, N=60, Not yet recruiting, Sponsor: Amgen
- ||| Aimovig (erenumab-aooe) / Amgen, Novartis
Trial completion date: LIBERTY: A Study Evaluating the Effectiveness of AMG 334 Injection in Preventing Migraines in Adults Having Failed Other Therapies (clinicaltrials.gov) - Apr 11, 2018
P3, N=246, Active, not recruiting, Sponsor: Novartis Pharmaceuticals
Active, not recruiting --> Recruiting Trial completion date: Jan 2019 --> Jan 2021
- |||| Aimovig (erenumab-aooe) / Amgen, Novartis
Trial primary completion date: LIBERTY: A Study Evaluating the Effectiveness of AMG 334 Injection in Preventing Migraines in Adults Having Failed Other Therapies (clinicaltrials.gov) - Mar 7, 2018
P3, N=246, Active, not recruiting, Sponsor: Novartis Pharmaceuticals
Trial completion date: Jan 2019 --> Jan 2021 Trial primary completion date: Jan 2019 --> Jan 2018
- || Aimovig (erenumab-aooe) / Amgen, Novartis
Trial primary completion date: Study of Erenumab (AMG 334) in Women With Hot Flashes (clinicaltrials.gov) - Feb 27, 2018
P1, N=103, Completed, Sponsor: Amgen
Trial primary completion date: Jan 2019 --> Jan 2018 Trial primary completion date: Aug 2014 --> Mar 2014
- |||||| Aimovig (erenumab-aooe) / Amgen, Novartis
Enrollment open, Trial initiation date: EMPOwER: Study of Efficacy and Safety of AMG 334 in Adult Episodic Migraine Patients (clinicaltrials.gov) - Feb 15, 2018
P3, N=880, Recruiting, Sponsor: Novartis Pharmaceuticals
Trial primary completion date: Aug 2014 --> Mar 2014 Not yet recruiting --> Recruiting | Initiation date: Feb 2018 --> Feb 2018
- | Aimovig (erenumab-aooe) / Amgen, Novartis
Trial completion: To Evaluate the Blockade of CGRP in Preventing PACAP-38 Induced Migraine-like Attacks With AMG 334 in Migraine Patients (clinicaltrials.gov) - Dec 8, 2017
P1, N=38, Completed, Sponsor: Amgen
Not yet recruiting --> Recruiting | Initiation date: Feb 2018 --> Feb 2018 Active, not recruiting --> Completed
- ||||| Aimovig (erenumab-aooe) / Amgen, Novartis
Enrollment closed: LIBERTY: A Study Evaluating the Effectiveness of AMG 334 Injection in Preventing Migraines in Adults Having Failed Other Therapies (clinicaltrials.gov) - Nov 9, 2017
P3, N=243, Active, not recruiting, Sponsor: Novartis Pharmaceuticals
Active, not recruiting --> Completed Recruiting --> Active, not recruiting
- |||||||||| Aimovig (erenumab-aooe) / Amgen, Novartis
New P3 trial: EMPOwER: Study of Efficacy and Safety of AMG 334 in Adult Episodic Migraine Patients (clinicaltrials.gov) - Nov 6, 2017
P3, N=880, Not yet recruiting, Sponsor: Novartis Pharmaceuticals
- Aimovig (erenumab-aooe) / Amgen, Novartis
Enrollment closed, Trial primary completion date: To Evaluate the Blockade of CGRP in Preventing PACAP-38 Induced Migraine-like Attacks With AMG 334 in Migraine Patients (clinicaltrials.gov) - Oct 25, 2017
P1, N=37, Active, not recruiting, Sponsor: Amgen
Recruiting --> Active, not recruiting Recruiting --> Active, not recruiting | Trial primary completion date: May 2018 --> Nov 2017
- ||||||| Aimovig (erenumab-aooe) / Amgen, Novartis
Trial completion: STRIVE: Study to Evaluate the Efficacy and Safety of Erenumab (AMG 334) in Migraine Prevention (clinicaltrials.gov) - Jun 23, 2017
P3, N=955, Completed, Sponsor: Amgen
Recruiting --> Active, not recruiting | Trial primary completion date: May 2018 --> Nov 2017 Active, not recruiting --> Completed
- |||| Aimovig (erenumab-aooe) / Amgen, Novartis
Trial completion: A Study to Assess the Long-term Safety and Efficacy of Erenumab (AMG 334) in Chronic Migraine Prevention. (clinicaltrials.gov) - Jun 2, 2017
P2, N=612, Completed, Sponsor: Amgen
Active, not recruiting --> Completed Active, not recruiting --> Completed
- |||| Aimovig (erenumab-aooe) / Amgen, Novartis
Trial completion: Treadmill Cardiovascular Safety Study of Erenumab (AMG 334) (clinicaltrials.gov) - May 11, 2017
P2, N=89, Completed, Sponsor: Amgen
Active, not recruiting --> Completed Active, not recruiting --> Completed
- ||| Aimovig (erenumab-aooe) / Amgen, Novartis
Enrollment closed: A Safety and Efficacy Study to Evaluate AMG 334 in Migraine Prevention (clinicaltrials.gov) - Apr 20, 2017
P2, N=475, Active, not recruiting, Sponsor: Amgen
Active, not recruiting --> Completed Recruiting --> Active, not recruiting
- |||||||||| Aimovig (erenumab-aooe) / Amgen, Novartis
New P3 trial: LIBERTY: A Study Evaluating the Effectiveness of AMG 334 Injection in Preventing Migraines in Adults Having Failed Other Therapies (clinicaltrials.gov) - Mar 30, 2017
P3, N=220, Recruiting, Sponsor: Novartis Pharmaceuticals
- Aimovig (erenumab-aooe) / Amgen, Novartis
Trial primary completion date: To Evaluate the Blockade of CGRP in Preventing PACAP-38 Induced Migraine-like Attacks With AMG 334 in Migraine Patients (clinicaltrials.gov) - Mar 28, 2017
P1, N=42, Recruiting, Sponsor: Amgen
Recruiting --> Active, not recruiting Trial primary completion date: Feb 2017 --> May 2018
- ||||||| Aimovig (erenumab-aooe) / Amgen, Novartis
Trial completion: ARISE: Study to Evaluate the Efficacy and Safety of Erenumab (AMG 334) Compared to Placebo in Migraine Prevention (clinicaltrials.gov) - Mar 27, 2017
P3, N=577, Completed, Sponsor: Amgen
Trial primary completion date: Feb 2017 --> May 2018 Active, not recruiting --> Completed
- ||| Aimovig (erenumab-aooe) / Amgen, Novartis
Enrollment closed, Enrollment change: Treadmill Cardiovascular Safety Study of Erenumab (AMG 334) (clinicaltrials.gov) - Feb 9, 2017
P2, N=89, Active, not recruiting, Sponsor: Amgen
Active, not recruiting --> Completed Recruiting --> Active, not recruiting | N=120 --> 89
- | Aimovig (erenumab-aooe) / Amgen, Novartis
Trial completion: Erenumab (AMG 334) Plus Combined Oral Contraceptive Drug Interaction Study in Healthy Females (clinicaltrials.gov) - Oct 11, 2016
P1, N=35, Completed, Sponsor: Amgen
Recruiting --> Active, not recruiting | N=120 --> 89 Active, not recruiting --> Completed
- | Aimovig (erenumab-aooe) / Amgen, Novartis
Trial completion: Study to Evaluate the Effect of Erenumab on Blood Pressure When Given Concomitantly With Subcutaneous Sumatriptan (clinicaltrials.gov) - Sep 13, 2016
P1, N=30, Completed, Sponsor: Amgen
Active, not recruiting --> Completed Active, not recruiting --> Completed
- Aimovig (erenumab-aooe) / Amgen, Novartis
Enrollment closed, Trial primary completion date: Study to Evaluate the Effect of Erenumab on Blood Pressure When Given Concomitantly With Subcutaneous Sumatriptan (clinicaltrials.gov) - Jun 9, 2016
P1, N=30, Active, not recruiting, Sponsor: Amgen
Active, not recruiting --> Completed Recruiting --> Active, not recruiting | Trial primary completion date: May 2016 --> Aug 2016
- | Aimovig (erenumab-aooe) / Amgen, Novartis
New P1 trial: Erenumab (AMG 334) Plus Combined Oral Contraceptive Drug Interaction Study in Healthy Females (clinicaltrials.gov) - Jun 9, 2016
P1, N=35, Active, not recruiting, Sponsor: Amgen
- |||| Aimovig (erenumab-aooe) / Amgen, Novartis
Trial completion: A Study to Evaluate the Efficacy and Safety of Erenumab (AMG 334) in Chronic Migraine Prevention (clinicaltrials.gov) - May 24, 2016
P2, N=667, Completed, Sponsor: Amgen
Recruiting --> Active, not recruiting | Trial primary completion date: May 2016 --> Aug 2016 Active, not recruiting --> Completed
- ||||| Aimovig (erenumab-aooe) / Amgen, Novartis
Enrollment closed: ARISE: Study to Evaluate the Efficacy and Safety of Erenumab (AMG 334) Compared to Placebo in Migraine Prevention (clinicaltrials.gov) - May 5, 2016
P3, N=577, Active, not recruiting, Sponsor: Amgen
Active, not recruiting --> Completed Recruiting --> Active, not recruiting
- ||||| Aimovig (erenumab-aooe) / Amgen, Novartis
Enrollment closed: STRIVE: Study to Evaluate the Efficacy and Safety of Erenumab (AMG 334) in Migraine Prevention (clinicaltrials.gov) - Apr 27, 2016
P3, N=955, Active, not recruiting, Sponsor: Amgen
Recruiting --> Active, not recruiting Recruiting --> Active, not recruiting
- | Aimovig (erenumab-aooe) / Amgen, Novartis
New P1 trial: Study to Evaluate the Effect of Erenumab on Blood Pressure When Given Concomitantly With Subcutaneous Sumatriptan (clinicaltrials.gov) - Apr 18, 2016
P1, N=30, Recruiting, Sponsor: Amgen
- Aimovig (erenumab-aooe) / Amgen, Novartis
Trial primary completion date: To Evaluate the Blockade of CGRP in Preventing PACAP-38 Induced Migraine-like Attacks With AMG 334 in Migraine Patients (clinicaltrials.gov) - Apr 13, 2016
P1, N=42, Recruiting, Sponsor: Amgen
Recruiting --> Active, not recruiting Trial primary completion date: Aug 2016 --> Feb 2017
- ||| Aimovig (erenumab-aooe) / Amgen, Novartis
Enrollment closed: A Study to Assess the Long-term Safety and Efficacy of Erenumab (AMG 334) in Chronic Migraine Prevention. (clinicaltrials.gov) - Mar 18, 2016
P2, N=612, Active, not recruiting, Sponsor: Amgen
Trial primary completion date: Aug 2016 --> Feb 2017 Recruiting --> Active, not recruiting
- |||| Aimovig (erenumab-aooe) / Amgen, Novartis
Trial primary completion date: ARISE: Study to Evaluate the Efficacy and Safety of Erenumab (AMG 334) Compared to Placebo in Migraine Prevention (clinicaltrials.gov) - Feb 8, 2016
P3, N=540, Recruiting, Sponsor: Amgen
Recruiting --> Active, not recruiting Trial primary completion date: Mar 2017 --> Jul 2016
- |||| Aimovig (erenumab-aooe) / Amgen, Novartis
Trial primary completion date: STRIVE: Study to Evaluate the Efficacy and Safety of Erenumab (AMG 334) in Migraine Prevention (clinicaltrials.gov) - Feb 2, 2016
P3, N=852, Recruiting, Sponsor: Amgen
Trial primary completion date: Mar 2017 --> Jul 2016 Trial primary completion date: May 2017 --> Aug 2016
- |||| Aimovig (erenumab-aooe) / Amgen, Novartis
Enrollment open: A Safety and Efficacy Study to Evaluate AMG 334 in Migraine Prevention (clinicaltrials.gov) - Jan 13, 2016
P2, N=459, Recruiting, Sponsor: Amgen
Trial primary completion date: May 2017 --> Aug 2016 Not yet recruiting --> Recruiting
- ||| Aimovig (erenumab-aooe) / Amgen, Novartis
Enrollment change: A Study to Assess the Long-term Safety and Efficacy of Erenumab (AMG 334) in Chronic Migraine Prevention. (clinicaltrials.gov) - Dec 17, 2015
P2, N=651, Recruiting, Sponsor: Amgen
Not yet recruiting --> Recruiting N=490 --> 651
- ||| Aimovig (erenumab-aooe) / Amgen, Novartis
Enrollment closed: A Study to Evaluate the Efficacy and Safety of Erenumab (AMG 334) in Chronic Migraine Prevention (clinicaltrials.gov) - Dec 15, 2015
P2, N=667, Active, not recruiting, Sponsor: Amgen
N=490 --> 651 Recruiting --> Active, not recruiting